76 related articles for article (PubMed ID: 36443153)
1. Comparing Risk for Second Primary Cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for Prostate Cancer, 2002-2015.
Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
[TBL] [Abstract][Full Text] [Related]
2. Intensity modulated radiotherapy for stage III non-small cell lung cancer in the United States: predictors of use and association with toxicities.
Shirvani SM; Jiang J; Gomez DR; Chang JY; Buchholz TA; Smith BD
Lung Cancer; 2013 Nov; 82(2):252-9. PubMed ID: 24018022
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic body radiation therapy versus intensity-modulated radiation therapy for prostate cancer: comparison of toxicity.
Yu JB; Cramer LD; Herrin J; Soulos PR; Potosky AL; Gross CP
J Clin Oncol; 2014 Apr; 32(12):1195-201. PubMed ID: 24616315
[TBL] [Abstract][Full Text] [Related]
4. Overall survival in low-comorbidity patients with stage I non-small cell lung cancer who chose stereotactic body radiotherapy compared to surgery.
Udelsman BV; Canavan ME; Zhan PL; Ely S; Park HS; Boffa DJ; Mase VJ
J Thorac Cardiovasc Surg; 2024 Mar; 167(3):822-833.e7. PubMed ID: 37500052
[TBL] [Abstract][Full Text] [Related]
5. National variation in the delivery of radiation oncology procedures in the non-facility-based setting.
Valle LF; Chu FI; Kundu P; Yoon SM; Gilchrist T; Steinberg ML; Raldow AC
Cancer Med; 2021 Jul; 10(14):4734-4742. PubMed ID: 34076341
[TBL] [Abstract][Full Text] [Related]
6. Pathologic Nodal Staging Before SBRT for Early-stage NSCLC Does Not Impact Overall Survival: A Propensity Score-matched NCDB Analysis.
Cantrell JN; Acharya P; Vesely SK; Gunter TC
Am J Clin Oncol; 2023 Nov; 46(11):503-511. PubMed ID: 37679872
[TBL] [Abstract][Full Text] [Related]
7. Adverse Events Following Limited Resection versus Stereotactic Body Radiation Therapy for Early Stage Lung Cancer.
Wang Q; Stone K; Kern JA; Slatore CG; Swanson S; Blackstock W; Khan RS; Smith CB; Veluswamy RR; Chidel M; Wisnivesky JP
Ann Am Thorac Soc; 2022 Dec; 19(12):2053-2061. PubMed ID: 35816617
[No Abstract] [Full Text] [Related]
8. Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era.
Abi Jaoude J; Thunshelle CP; Kouzy R; Nguyen ND; Lin D; Prakash L; Bumanlag IM; Noticewala SS; Niedzielski JS; Beddar S; Ludmir EB; Holliday EB; Das P; Minsky BD; Herman JM; Katz M; Koong AC; Koay EJ; Taniguchi CM
Adv Radiat Oncol; 2021; 6(6):100763. PubMed ID: 34934858
[TBL] [Abstract][Full Text] [Related]
9. Percutaneous local tumor ablation vs. stereotactic body radiotherapy for early-stage non-small cell lung cancer: a systematic review and meta-analysis.
Chen D; Zhao M; Xiang X; Liang J
Chin Med J (Engl); 2022 Jul; 135(13):1517-24. PubMed ID: 35830244
[TBL] [Abstract][Full Text] [Related]
10. Photodynamic therapy for stage I and II non-small cell lung cancer: A SEER-Medicare analysis 2000-2016.
Chhatre S; Murgu S; Vachani A; Jayadevappa R
Medicine (Baltimore); 2022 Mar; 101(11):. PubMed ID: 35356921
[TBL] [Abstract][Full Text] [Related]
11. Local coverage determination policy and the use of stereotactic body radiation therapy for prostate cancer.
Jacobs BL; Sunderland R; Yabes J; Nelson JB; Barnato AE; Bekelman JE
Urol Pract; 2015 Nov; 2(6):304-311. PubMed ID: 27493987
[TBL] [Abstract][Full Text] [Related]
12. Lung cancer. Radiotherapy in lung cancer: Actual methods and future trends.
Maciejczyk A; Skrzypczyńska I; Janiszewska M
Rep Pract Oncol Radiother; 2014 Nov; 19(6):353-60. PubMed ID: 25337407
[TBL] [Abstract][Full Text] [Related]
13. Proton SBRT is ready to move past uncertainties and towards improved clinical outcomes.
Simone CB; Lin L
J Radiosurg SBRT; 2023; 9(1):3-6. PubMed ID: 38029009
[No Abstract] [Full Text] [Related]
14. Radiation-induced lung injury after breast cancer treatment: incidence in the CANTO-RT cohort and associated clinical and dosimetric risk factors.
Gueiderikh A; Sarrade T; Kirova Y; De La Lande B; De Vathaire F; Auzac G; Martin AL; Everhard S; Meillan N; Bourgier C; Benyoucef A; Lacornerie T; Pasquier D; Racadot S; Moignier A; Paris F; André F; Deutsch E; Duchemann B; Allodji RS; Rivera S
Front Oncol; 2023; 13():1199043. PubMed ID: 37456251
[TBL] [Abstract][Full Text] [Related]
15. Radiation combined with immune checkpoint inhibitors for unresectable locally advanced non-small cell lung cancer: synergistic mechanisms, current state, challenges, and orientations.
Wu L; Zhang Z; Bai M; Yan Y; Yu J; Xu Y
Cell Commun Signal; 2023 May; 21(1):119. PubMed ID: 37221584
[TBL] [Abstract][Full Text] [Related]
16. A nomogram for the prediction of the survival of patients with advanced non-small cell lung cancer and interstitial lung disease.
Xiu W; Zheng J; Zhou Y; Du H; Li J; Li W; Zhou F; Zhou C; Wu F
Cancer Med; 2023 May; 12(10):11375-11384. PubMed ID: 36999934
[TBL] [Abstract][Full Text] [Related]
17. Non-Small Cell Lung Cancer Treatment with Molecularly Targeted Therapy and Concurrent Radiotherapy-A Review.
Król K; Mazur A; Stachyra-Strawa P; Grzybowska-Szatkowska L
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982933
[TBL] [Abstract][Full Text] [Related]
18. Outcomes Following SBRT vs. IMRT and 3DCRT for Older Patients with Stage IIA Node-Negative Non-Small Cell Lung Cancer > 5 cm.
Tran JH; Mhango G; Park HS; Marshall DC; Rosenzweig KE; Wang Q; Wisnivesky JP; Veluswamy RR
Clin Lung Cancer; 2023 Jan; 24(1):e9-e18. PubMed ID: 36443153
[TBL] [Abstract][Full Text] [Related]
19. Risk of Cardiovascular Toxicity According to Tumor Laterality Among Older Patients With Early Stage Non-small Cell Lung Cancer Treated With Radiation Therapy.
Liu BY; Rehmani S; Kale MS; Marshall D; Rosenzweig KE; Kong CY; Wisnivesky J; Sigel K
Chest; 2022 Jun; 161(6):1666-1674. PubMed ID: 35063448
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
